Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Phase II study of AK150 in knee osteoarthritis
jRCT2080221101Phase 2
- Sponsor
- Asahi Kasei Corporation
- Start
- May 2010
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in knee osteoarthritis (OA) comparing AK150 with Placebo (2 arms).
02
Drugs
AK150
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2080221101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221101.